Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

Inclusion Criteria: Eligibility will be determined separately for Part I and Part II of this study: Part I ( Part I Eligibility criteria (eligibility for undergoing apheresis procedure) Age ≤ 25 years at initial diagnosis. Must have one of the following diagnoses: High risk neuroblastoma Metastatic or recurrent retinoblastoma High risk rain tumors Recurrent or refractory Hodgkin disease Recurrent or advanced stage Wilms tumor Recurrent or metastatic sarcomas Recurrent or refractory non-Hodgkin lymphoma Desmoplastic small round cell tumor. Lansky or Karnofsky Performance Score ≥ 70. Creatinine ≤ 2.0 mg/dl. Direct bilirubin ≤ 2.0 mg/dl. SGPT ≤ 2 x upper limit of normal HIV testing Negative pregnancy test Patients with significant prior radiation therapy to the liver will be excluded. Part II eligibility criteria (criteria for transplantation of CD133 select stem cell product) Successfully completed Part I of protocol treatment plan and has the following available: Stored autologous bone marrow or peripheral blood stem cells (i.e. 2 x 106 unselected CD34+ cells/ kg PBSC or 1 x 106 CD34+ cells/ kg BM) for back up. Stored autologous bone marrow or peripheral blood stem cells (2 x 106 CD133+ cells/ kg PBSC or 2 x 106 CD133+ cells/ kg BM) for infusion. Forced vital capacity greater than or equal to 40% normal or pulse oximetry greater than or equal to 92% on room air. Lansky or Karnofsky Performance Score ≥ 70. Creatinine ≤ 2.0 mg/dl. Direct bilirubin ≤ 2.0 mg/dl. SGPT ≤ 2 x upper limit of normal Negative pregnancy test Patients with significant prior radiation therapy (in opinion of the PI) to the liver will be excluded.